Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$19.67 USD

19.67
4,324,041

+0.84 (4.46%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $19.68 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Alnylam (ALNY) Reports Positive Results From APOLLO-B Study

by Zacks Equity Research

Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.

Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now

by Zacks Equity Research

Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.

Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%

by Zacks Equity Research

Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.

Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing

by Zacks Equity Research

Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.

Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag

by Zacks Equity Research

Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 40% and 10.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

by Zacks Equity Research

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -33.33% and 1.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates

by Zacks Equity Research

Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.

Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

by Zacks Equity Research

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.

Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.

Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.

Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss

by Zacks Equity Research

Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.

Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.

Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.

Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio

by Zacks Equity Research

Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

by Zacks Equity Research

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

by Zacks Equity Research

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.

Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails

by Zacks Equity Research

Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

by Zacks Equity Research

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.

Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study

by Zacks Equity Research

Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.